{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"28"}]}],"title":"Complete Response + Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"23"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"32"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"}]}],"title":"Progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}],"title":"Not Evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"description":"A rigorous composite assessment was employed with uni-dimensional measurements of skin and visceral disease sites assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) required clearing of all known disease sites. Partial response (PR) required documented response in skin (≥ 30% per RECIST) or lymph nodes (≥ 50% per the International Working Group (IWG) criteria, with response in both compartments for a determination of PR, IWG guidelines. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive disease (PD) is at least a 20% increase in the sum of the target lesions, or the appearance of one or more new lesions. Lymph node disease was assessed bi-dimensionally using the IWG criteria. Bone marrow involvement, as recommended by IWG criteria, and presence of circulating malignant T-cells ascertained by flow cytometry.","groups":[{"description":"Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\\^2 and at 17.5 mg/m\\^2 on days 1, 8, and 15 of a 28 day cycle.","id":"OG000","title":"Peripheral T-cell Lymphoma (PTCL)"},{"description":"Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\\^2 and at 17.5 mg/m\\^2 on days 1, 8, and 15 of a 28 day cycle.","id":"OG001","title":"Cutaneous T-cell Lymphoma (CTCL)"}],"paramType":"NUMBER","populationDescription":"Two participants were excluded. After further analysis it was determined that the participants did not have PTCL but a different form of lymphoma that was not known at the onset of enrollment.","reportingStatus":"POSTED","timeFrame":"up to 56.5 days","title":"Number of Participants With a Response","type":"PRIMARY","unitOfMeasure":"participants"}